Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv30-iv40. doi: 10.1093/annonc/mdy133.
No abstract available

Publication types

  • Practice Guideline

MeSH terms

  • Administration, Cutaneous
  • Aftercare / methods
  • Aftercare / standards
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / standards
  • Biomarkers, Tumor / genetics
  • CD79 Antigens / genetics
  • Chemoradiotherapy / methods
  • Dermatologic Surgical Procedures / methods
  • Dermatologic Surgical Procedures / standards
  • Europa
  • Humans
  • Incidence
  • Lymphoma, B-Cell / diagnosis
  • Lymphoma, B-Cell / epidemiology
  • Lymphoma, B-Cell / pathology
  • Lymphoma, B-Cell / therapy*
  • Lymphoma, T-Cell, Cutaneous / diagnosis
  • Lymphoma, T-Cell, Cutaneous / epidemiology
  • Lymphoma, T-Cell, Cutaneous / pathology
  • Lymphoma, T-Cell, Cutaneous / therapy*
  • Medical Oncology / methods
  • Medical Oncology / standards*
  • Myeloid Differentiation Factor 88 / genetics
  • Neoplasm Staging
  • Ointments
  • Precision Medicine / methods
  • Precision Medicine / standards*
  • Skin / drug effects
  • Skin / pathology
  • Skin Neoplasms / diagnosis
  • Skin Neoplasms / epidemiology
  • Skin Neoplasms / pathology
  • Skin Neoplasms / therapy*
  • Societies, Medical / standards
  • Survivorship
  • Treatment Outcome
  • Ultraviolet Therapy / methods
  • Ultraviolet Therapy / standards

Substances

  • Biomarkers, Tumor
  • CD79 Antigens
  • CD79B protein, human
  • MYD88 protein, human
  • Myeloid Differentiation Factor 88
  • Ointments